Benign breast diseases: Classification, diagnosis, and management [1]

Oncologist

Volumn 11, Issue 10, 2006, Pages 1132-1134

  Mannello, Ferdinando ^a   Tonti, Gaetana A M ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

BREAST CANCER; BREAST CYST; BREAST DISEASE; CANCER DIAGNOSIS; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL FEATURE; DISEASE CLASSIFICATION; HISTOPATHOLOGY; HUMAN; HYPERPLASIA; LETTER; MALIGNANT TRANSFORMATION; MASTALGIA; PRIORITY JOURNAL; SELF EXAMINATION;

BREAST DISEASES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS;

EID: 33751214201     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-10-1132     Document Type: Letter

References (30)

1. Guray M, Sahin AA. Benign breast diseases: classification, diagnosis, and management. The Oncologist 2006;11:435-449.
2. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005;353:275-285.
3. Haagensen DE, Haagensen CD. Breast Carcinoma: Risk and Detection. Philadelphia: W.B. Saunders, 1997:1-1064.
4. Love SM, Lindsey K, Williams M. Dr Susan Love's Breast Book, Fourth Edition. Cambridge MA: DaCapoPress, 2005:1-632.
5. Mannello F, Tonti GAM, Papa S. Human gross cyst breast disease and cystic fluid: bio-molecular, morphological, and clinical studies. Breast Cancer Res Treat 2006;97:115-129.
6. Miller WR, Dixon JM, Scott WN et al. Classification of human breast cysts according to electrolyte and androgen conjugate composition. Clin Oncol 1983;9:227-232.
7. Angeli A, Dogliotti L, Naldoni C et al. Steroid biochemistry and categorization of breast cyst fluid: relation to breast cancer risk. J Steroid Biochem Mol Biol 1994;49:333-339.
8. Malatesta M, Mannello F, Sebastiani M et al. Ultrastructural characterization and biochemical profile of human gross cystic breast disease. Breast Cancer Res Treat 1998;48:211-219.
9. Mannello F, Malatesta M, Gazanelli G. Breast cancer in women with palpable breast cysts. Lancet 1999;354:677-678.
10. Marchant DJ. Benign breast disease. Obstet Gynecol Clin North Am 2002;29:1-20.
11. Naldoni C, Costantini M, Dogliotti L et al. Association of cyst type with risk factors for breast cancer and relapse rate in women with gross cystic disease of the breast. Cancer Res 1992;52:1791-1795.
12. Dixon JM, McDonald C, Elton RA et al. Risk of breast cancer in women with palpable breast cysts: a prospective study. Lancet 1999;353:1742-1745.
13. Masood S. Cytomorphology of fibrocystic change, high risk proliferative breast disease, and premalignant breast lesions. Clin Lab Med 2005;25:713-731.
14. Tsung JSH, Wang TY, Wang SM et al. Cytological and biochemical studies of breast cyst fluid. Breast 2005;14:37-41.
15. Zanardi S, Pensa F, Torrisi R et al. Presence and distribution of growth factors in breast cyst fluid. Ann N Y Acad Sci 1996;784:542-549.
16. Budai B, Szamel I, Sulyok Z et al. Influence of hormonal status of patients with cystic disease on the composition of cyst fluid and breast cancer risk. Anticancer Res 2000;20:3879-3886.
17. Mannello F, Gazzanelli G. Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics? Breast Cancer Res 2001;3:238-243.
18. Hutter RVP. Good-bye to "fibrocystic disease." N Engl J Med 1985;312:179-181.
19. Bodian CA, Lattes R, Perzin KH. The epidemiology of gross cystic disease of the breast confirmed by biopsy or by aspiration of cyst fluid. Cancer Detect Prev 1992;16:7-15.
20. Hamed H, Coady A, Chaudary M et al. Follow-up of patients with aspirated breast cysts is necessary. Arch Surg 1989;124:253-255.
21. Lucas JH, Cone DL. Breast cyst aspiration. Am Fam Physician 2003;68:1983-1986.
22. Jemal A, Siegel R, Ward E et al. Cancer statistics 2006. CA Cancer J Clin 2006;56:106-130.
23. Daly MB, Ross EA. Predicting breast cancer: the search for a model. J Natl Cancer Inst 2000;92:1196-1197.
24. Fabian CJ, Kimler BF, Mayo MS et al. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 2005;12:185-213.
25. Alexander H, Stegner AL, Wagner-Mann C et al. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 2004;10:7500-7510.
26. Mannello F, Sebastiani M. Zymographic analyses and measurement of matrix metalloproteinase-2 and -9 in nipple aspirate fluids. Clin Chem 2003;49:1546-1550.
27. Zhu W, Qin W, Bradley P et al. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate f luid. Carcinogenesis 2005;26:145-152.
28. Tice JA, Miike R, Adduci K et al. Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Cancer Epidemiol Biomarkers Prev 2005;14:324-328.
29. Fabian CJ, Kimler BF. Breast cancer chemoprevention: current challenges and look toward the future. Clin Breast Cancer 2002;3:113-124.
30. Sauter ER. Analysis of nipple aspirate fluid for diagnosis of breast cancer: an alternative to invasive biopsy. Expert Rev Mol Diagn 2005;5:873-881.